Dubai – NanoCellect Biomedical Inc. a privately-held life sciences company, focused on developing microfluidic based cell analysis and sorting solutions, has signed an agreement appointing Alliance Global (AGBL Group) as the exclusive distributor in the Middle East, Africa, Levant, Turkey, Pakistan, Bangladesh and Sri Lanka.
Dr. Will Alaynick, Co-founder and Vice President International at NanoCellect commented that, “NanoCellect is eagerly supporting our colleagues in performing cell line development and single-cell ‘omics research. In addition, we have helped numerous infectious disease researchers with our sterile, contained cartridges—including the novel coronavirus. Reaching additional researchers in Africa who are addressing malaria, and several viral diseases is what makes our efforts at NanoCellect so rewarding.”
“We are very happy to establish a strategic partnership with NanoCellect. We believe that NanoCellect’s products will add great value to our customers and markets.” said Dr. Nassim-Marie Hambouz, AGBL’s Vice President of Commercial Operations.
About AGBL
Alliance Global Group of companies is the largest biomedical gateway in the Middle East, Africa, and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the region’s emerging healthcare market. The group's mission is to improve lives through novel biomedical technologies and products. For more information visit www.agbl.net.
About NanoCellect Biomedical
NanoCellect’s mission is to facilitate breakthrough biomedical discoveries by making cell sorting and analysis technology portable, affordable, and easy to use. Its WOLF platform is used in a growing number of scientific applications including antibody discovery, cell line development, single cell genomics, genomic sample preparation, CRISPR genomic editing, and plant and animal genomics. For more information, visit https://nanocellect.com/
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
